---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002536"
form_type: "8-K"
ticker: null
cik: "0001766267"
company_name: "Synergy Empire Ltd"
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:43:27.245016+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Synergy Empire acquires Meluha Therapeutics for $2.3M in preferred stock; shifts to stem cell medicine

## Summary
- Acquired 100% of Meluha Therapeutics on March 28, 2025, for 10M Series A preferred shares valued at $2.3M.
- Company pivots from F&B consultancy to biopharmaceutical manufacturing of stem cell therapies.
- Meluha directors Ramesh A/L Saravanamuthu and Abdul Jalil bin Jidon received 3.36M and 3.19M preferred shares respectively.
- No financial details of Meluha (revenue/profit) disclosed in the filing.

## SEC filing metadata
- accession: 0001641172-25-002536
- form_type: 8-K
- cik: 0001766267
- company_name: Synergy Empire Ltd
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766267/000164117225002536/0001641172-25-002536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766267/000164117225002536/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002536
- JSON: https://secwatch.observer/filing/0001641172-25-002536.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002536.txt

## Key facts
- M&A Transactions
  Synergy Empire Ltd completed an acquisition involving Meluha Therapeutics Berhad for 10,000,000 shares of Series A preferred stock valued at $0.23 per share for an aggregate value of $2,300,000 (closed 2025-03-28).
  - Action: acquisition
  - Counterparty: Meluha Therapeutics Berhad
  - Consideration: 10,000,000 shares of Series A preferred stock valued at $0.23 per share for an aggregate value of $2,300,000
  - Closing: 2025-03-28
  source text: Meluha Therapeutics Berhad (“Meluha”), a limited company incorporated under the laws of Malaysia, and the shareholders of Meluha. Pursuant to the Agreement, we agreed to purchase 10,000,000 shares of Meluha (the “Meluha Shares”), representing all of the issued and outstanding shares of common stock of Meluha, which were held by all the shareholders of Meluha. As a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766267/000164117225002536/0001641172-25-002536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.